NCT01437592View on ClinicalTrials.gov

Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 6, 2011

Primary Completion Date

November 22, 2011

Study Completion Date

November 22, 2011

Conditions

DiabetesHealthy

Interventions

DRUG

insulin degludec

For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)

Trial Locations (1)

100032

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter